Phase II trial of sorafenib in advanced thyroid cancerVandana Gupta-Abramson
Developmental TherapeuticsProgram of the Abramson CancerCenter, University of Pennsylvania, Philadelphia, PA 19104, USA
J Clin Oncol 26:4714-9. 2008
....
- Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
Paolo A Ascierto
Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
J Transl Med 10:83. 2012
....
- Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"
Paolo A Ascierto
Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
J Transl Med 9:32. 2011
..Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies...
Sorafenib in renal cell carcinomaKeith T Flaherty
Abramson Cancer Center, University of Pennsylvania, 51 North 39th Street, Philadelphia, PA 19104, USA
Clin Cancer Res 13:747s-752s. 2007
..Preliminary evidence with this approach is promising and will be the subject of the next generation of randomized trials in renal cell carcinoma...
BRAF, a target in melanoma: implications for solid tumor drug developmentKeith T Flaherty
Division of Hematology Oncology, Massuchusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Cancer 116:4902-13. 2010
..The current investigations in melanoma will create a set of hypotheses to be tested in each cancer that harbors BRAF mutations...
- Sorafenib: delivering a targeted drug to the right targets
Keith T Flaherty
University of Pennsylvania, Abramson Cancer Center, PA 19104, USA
Expert Rev Anticancer Ther 7:617-26. 2007
..A detailed discussion of the clinical trials in renal cell carcinoma, melanoma and hepatocellular carcinoma highlights what is known and what has yet to be understood about this agent...
- Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
Keith T Flaherty
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Cancer Biol Ther 7:496-501. 2008
..Sorafenib is a novel RAF and VEGF receptor tyrosine kinase inhibitor. We conducted this study to (a) determine if sorafenib is anti-angiogenic, and (b) to relate anti-angiogenic effect to outcome...
- Chemotherapy and targeted therapy combinations in advanced melanoma
Keith T Flaherty
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Clin Cancer Res 12:2366s-2370s. 2006
..The mechanism by which signaling inhibition might synergize with chemotherapy requires more study so that rational combinations move forward. Very few targeted agents have been studied rigorously in this fashion...
- A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
Keith T Flaherty
The Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Clin Cancer Res 14:4836-42. 2008
..Pharmacokinetic analyses were done for sorafenib on days 2 and 19 of cycle 1 and for paclitaxel on day 1 of cycles 1 and 2. Pretreatment tumor samples from 17 melanoma patients were analyzed for BRAF mutations...
- The future of tyrosine kinase inhibitors: single agent or combination?
Keith T Flaherty
Abramson Cancer Center, University of Pennsylvania, 12 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA
Curr Oncol Rep 10:264-70. 2008
..A careful consideration of the specific mechanism of action of each agent provides a basis for considering the optimal therapeutic strategies for incorporating each of these agents into the management of metastatic RCC...
- Antisense therapeutics: lessons from early clinical trials
K T Flaherty
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
Curr Opin Oncol 13:499-505. 2001
..Antisense oligodeoxynucleotides against bcl-2, c-raf-1, and protein kinase C-alpha continue to be the focus of ongoing trials...
- Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer
Keith T Flaherty
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Cancer 97:1985-90. 2003
..The authors performed a dose escalation study of cisplatin and the novel deoxycytidine analog, tezacitabine, to determine the maximum tolerated dose of the combination...
- New molecular targets in melanoma
Keith T Flaherty
Instructor of Medicine, Abramson Cancer Center of the University of Pennsylvania, 51 N 39th Street, MAB 103, Philadelphia, PA 19104, USA
Curr Opin Oncol 16:150-4. 2004
..Therapies that target the molecular pathophysiology of metastatic melanoma provide hope that more effective treatments will soon be available...
- A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine
Keith T Flaherty
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA 19104, USA
Cancer Chemother Pharmacol 53:404-8. 2004
..In single-agent studies of ZD0473, myelosuppression was the predominant toxicity and responses wer observed...
- Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation
John P Plastaras
Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Cancer Res 67:9443-54. 2007
..This study establishes a foundation for clinical testing of sequential fractionated radiation followed by sorafenib in gastrointestinal and other malignancies...
- Phase I trial of combretastatin a-4 phosphate with carboplatin
Joshua H Bilenker
University of Pennsylvania Cancer Center, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA
Clin Cancer Res 11:1527-33. 2005
..Preclinical evidence of synergy led to a phase I trial employing combretastatin A-4 phosphate (CA4P), a novel tubulin-binding antivascular drug, in combination with carboplatin...
- Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study
Keith T Flaherty
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
Cancer Chemother Pharmacol 68:1111-8. 2011
....
- Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma
Allireza Alloo
Department of Dermatology, Brigham and Women s Hospital, Boston, MA 02115, USA
Arch Dermatol 148:363-6. 2012
..With multiple such neoplasms often arising after BRAF inhibitor therapy, surgical excision is often impractical...
- Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
Andrea Boni
Division of Surgical Oncology, Medical Oncology, and Dermatology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Cancer Res 70:5213-9. 2010
..These findings have important implications for combined kinase-targeted therapy plus immunotherapy for melanoma...
- MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib
Hyunseon Christine Kang
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
AJR Am J Roentgenol 200:120-6. 2013
..The purpose of this study was to examine early MRI changes in renal cell carcinoma (RCC) treated with the antiangiogenic agent sorafenib and to identify MRI biomarkers of RCC response to sorafenib...
- Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression
Keiran S M Smalley
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
Cancer Res 68:5743-52. 2008
..This group of melanomas may be a subpopulation for which imatinib or other KIT inhibitors may constitute optimal therapy...
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Keith T Flaherty
Massachusetts General Hospital Cancer Center, Boston, USA
N Engl J Med 367:1694-703. 2012
..To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor...
- Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer
Keith T Flaherty
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
Clin Cancer Res 18:568-76. 2012
....
- Mechanisms of hypertension associated with BAY 43-9006
Maria Luisa Veronese
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
J Clin Oncol 24:1363-9. 2006
..CONCLUSION: Treatment with BAY 43-9006 is associated with a significant and sustained increase in BP. The lack of significant change in circulating factors suggests that these humoral factors had little role in the increase in BP...
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S M Smalley
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
Mol Cancer Ther 7:2876-83. 2008
....
- Drug targeting of oncogenic pathways in melanoma
Leslie A Fecher
Department of Medicine, Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, 3400 Spruce Street, 16 Penn Tower, Philadelphia, PA 19104, USA
Hematol Oncol Clin North Am 23:599-618, x. 2009
..The targeting of certain cellular processes, downstream of the common genetic alterations, for which the issues of target and drug validation are somewhat distinct, are also highlighted...
- Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy
Daniel C Cho
Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Cancer 118:6055-62. 2012
....
- Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
Keith T Flaherty
Massachusetts General Hospital, 55 Fruit St, Yawkey 9E, Boston, MA 02114, USA
J Clin Oncol 31:373-9. 2013
..The primary objective of this study was to determine whether carboplatin, paclitaxel, and sorafenib (CPS) improve overall survival (OS) compared with carboplatin and paclitaxel (CP) in chemotherapy-naive patients with metastatic melanoma...
- p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition
Zhenyu Ji
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
J Invest Dermatol 132:356-64. 2012
..These results provide fundamental insights into the intact p53 circuitry, which can be restored through small molecule inhibitors and potentially deployed for therapeutic gain...
- HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma
John D Gordan
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Cancer Cell 14:435-46. 2008
..These reproducible distinctions in ccRCC behavior delineate HIF-alpha effects on c-Myc in vivo and suggest molecular criteria for selecting targeted therapies...
- Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
Keiran S M Smalley
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
Mol Cancer Ther 5:1136-44. 2006
..It is further suggested that BRAF mutational status is not predictive of response to MEK inhibition under three-dimensional culture conditions...
- EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
Ryan B Corcoran
Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
Cancer Discov 2:227-35. 2012
....
- New challenges in endpoints for drug development in advanced melanoma
Antoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, CA90095, USA
Clin Cancer Res 18:336-41. 2012
....
- Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy
Keith T Flaherty
Abramson Cancer Center, University of Pennsylvania, Medical Arts Buildingm Suite 103, 39th and Market Streets, Philadelphia, PA 19104, USA
Cancer Chemother Pharmacol 52:217-22. 2003
..The antitumor activity noted suggests that further investigation of this well-tolerated combination in specific tumor types, especially NSCLC, is warranted...
- Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
Leslie A Fecher
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
J Natl Compr Canc Netw 7:295-304. 2009
..This article explores the factors to consider when individualizing care within the scope of these guidelines...
- Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets
Keith T Flaherty
Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St, Yawkey 9E, Boston, MA 02114, USA
Clin Exp Metastasis 29:841-6. 2012
....
- Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies
Joshua H Bilenker
Abramson Family Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
Cancer Chemother Pharmacol 53:357-60. 2004
..The combination shows evidence of antitumor activity in a pretreated population...
- Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H Vonderheide
Abramson Family Cancer Research Institute, Abramson Cancer Center, Division of Hematology Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Clin Oncol 25:876-83. 2007
..CD40 is also expressed by solid tumors, but its engagement results in apoptosis. CP-870,893, a fully human and selective CD40 agonist monoclonal antibody (mAb), was tested for safety in a phase I dose-escalation study...
- Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference
Michael B Atkins
Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
Clin Cancer Res 13:667s-670s. 2007
....
- Inhibition of mutated, activated BRAF in metastatic melanoma
Keith T Flaherty
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA
N Engl J Med 363:809-19. 2010
..The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease...
- MEK and RAF inhibitors for BRAF-mutated cancers
Sarah Belden
Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
Expert Rev Mol Med 14:e17. 2012
....
- From genes to drugs: targeted strategies for melanoma
Keith T Flaherty
Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, Massachusetts 02114, USA
Nat Rev Cancer 12:349-61. 2012
..This Review focuses on these recent striking advances in the strategy of molecularly targeted approaches to the therapy of melanoma in humans...
- Improved survival with MEK inhibition in BRAF-mutated melanoma
Keith T Flaherty
Massachusetts General Hospital Cancer Center, Boston, USA
N Engl J Med 367:107-14. 2012
..Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population...
- Targeting metastatic melanoma
Keith T Flaherty
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
Annu Rev Med 63:171-83. 2012
..Ongoing translational research seeks to identify the most scientifically rational combination treatment strategies to build on single-agent targeted therapy...
- Targeting the RAS pathway in melanoma
Zhenyu Ji
Wellman Center for Photomedicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
Trends Mol Med 18:27-35. 2012
..In this review, the current state of targeted therapy for melanoma is discussed, including the potent BRAF(V600E) inhibitor vemurafenib...
- Is ERK activation a good biomarker for estradiol and tamoxifen effects?
Keiran S M Smalley
Wistar Institute, Philadelphia, Pennsylvania, USA
Cancer Biol Ther 6:119-20. 2007
- The MAPK pathway in melanoma
Leslie A Fecher
University of Pennsylvania, Division of Hematology and Oncology, Department of Medicine, The Abramson Cancer Center, Philadelphia, Pennsylvania 19104, USA
Curr Opin Oncol 20:183-9. 2008
..Several therapeutic agents directed against this pathway are in development. This review summarizes current understanding of the MAPK pathway in melanoma biology and therapeutic strategies...
- Her-2 targeted therapy: beyond breast cancer and trastuzumab
Keith T Flaherty
Abramson Cancer Center of the University of Pennsylvania, 51 N 39th Street, MAB 103, Philadelphia, PA 19104, USA
Curr Oncol Rep 8:90-5. 2006
..Preliminary results from early clinical trials suggest that Her-2 tyrosine kinase inhibitors may extend the population for which this strategy offers therapeutic effect...
- BRAF targeted therapy changes the treatment paradigm in melanoma
Antoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, and Jonsson Comprehensive Cancer Center at UCLA, 11 934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Nat Rev Clin Oncol 8:426-33. 2011
..Vemurafenib (PLX4032) and GSK2118436, two orally available and well tolerated agents are on the verge of transforming the landscape of melanoma therapy based on the promising results of their respective phase I, II, and III trials...
- Narrative review: BRAF opens the door for therapeutic advances in melanoma
Keith T Flaherty
Massachusetts General Hospital Cancer Center, Boston, 02114, USA
Ann Intern Med 153:587-91. 2010
..Clinicians should be aware of phase 3 trials of these agents and trials combining these therapies with other novel therapies because, at a minimum, BRAF inhibitors seem to be valuable as palliative therapy for metastatic melanoma...
- An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells
Keiran S M Smalley
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
Cancer Res 67:209-17. 2007
..Taken together, our data provide a new strategy for the pharmacologic activation of p53 in melanoma, which may be a viable approach for overcoming apoptotic resistance in melanoma and offer new hope for rational melanoma therapy...
- Targeted therapy for metastatic melanoma
Ravi K Amaravadi
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
Clin Adv Hematol Oncol 5:386-94. 2007
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Lawrence N Kwong
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
Nat Med 18:1503-10. 2012
..Such a gated signaling model offers a new framework to identify nonobvious coextinction target(s) for combined pharmacological inhibition in NRAS-mutant melanomas...
- BRAF inhibitors and melanoma
Keith T Flaherty
Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
Cancer J 17:505-11. 2011
..Opportunities for combining BRAF inhibitors with other signal transduction inhibitors as well as targeted therapies with distinct mechanisms of action are discussed...
- VEGFR-targeted therapy
Keith T Flaherty
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
Clin Adv Hematol Oncol 3:371-2. 2005
- New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances
Keith T Flaherty
Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
Clin Cancer Res 17:4922-8. 2011
..The melanoma field stands poised to take the lead among cancer subtypes in advancing combination therapy strategies that simultaneously target multiple biologic underpinnings of the disease...
- Molecular therapeutic approaches to melanoma
Zhenyu Ji
Wellman Center for Photomedicine Dept of Dermatology, 55 Fruit Street, Boston, MA 02114, USA
Mol Aspects Med 31:194-204. 2010
....
- Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death
M Stacey Ricci
Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Cancer Cell 12:66-80. 2007
..Combining sorafenib with TRAIL in vivo showed dramatic efficacy in TRAIL-resistant tumor xenografts. We propose the combination of TRAIL with sorafenib holds promise for further development...
- BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
Dennie T Frederick
Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Clin Cancer Res 19:1225-31. 2013
..To evaluate the effects of BRAF inhibition on the tumor microenvironment in patients with metastatic melanoma...
- The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling
Brijal M Desai
The Wistar Institute, Philadelphia, Pennsylvania, United States of America
PLoS ONE 8:e59588. 2013
..Altogether, these data show that dinaciclib induces apoptosis in a large panel of melanoma cell lines through a mechanism requiring p53 expression...
- Innovations and challenges in melanoma: summary statement from the first Cambridge conference
Michael B Atkins
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Clin Cancer Res 12:2291s-2296s. 2006
....
- HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest
Wei Jiang
Division of Endocrine and Oncologic Surgery, Department of Surgery, University of Pennsylvania Medical Center, 4 Silverstein, 3400 Spruce Street, Philadelphia, PA 19104, USA
Cancer Res 67:1221-7. 2007
..Our results suggest that nelfinavir is a promising candidate chemotherapeutic agent for advanced melanoma, for which novel and effective therapies are urgently needed...
- Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers
Erica L Carpenter
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Clin Cancer Res 15:4277-87. 2009
..This study aimed to investigate whether B-cell physiology was altered in the presence of melanoma and other cancers...
- A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States)
Keith T Flaherty
Department of Medicine, Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
Cancer Causes Control 16:1099-106. 2005
..CONCLUSIONS: Diagnosis of hypertension, higher BMI, and increasing pack-years of smoking appear to independently increase the risk of renal cell carcinoma...
- Mutation-driven drug development in melanoma
Keith T Flaherty
Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
Curr Opin Oncol 22:178-83. 2010
..The purpose of this review is to define those oncogenes for which there are preclinical data supporting clinical trials and to summarize results from clinical investigations...
- Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
Mark J Ratain
University of Chicago, Chicago, IL 60637, USA
J Clin Oncol 24:2505-12. 2006
..This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and vasculature, on tumor growth in patients with metastatic renal cell carcinoma...
- CCR drug updates: sorafenib and sunitinib in renal cell carcinoma
Mark N Stein
Department of Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA
Clin Cancer Res 13:3765-70. 2007
- Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
Konstantinos G Lasithiotakis
Division of Dermatologic Oncology, Department of Dermatology, University of Tuebingen, Tuebingen, Germany
J Invest Dermatol 128:2013-23. 2008
..Sorafenib combined with rapamycin appears to be a promising strategy for the effective treatment of melanoma and merits clinical investigation...
- Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma
Mary M McCarthy
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Clin Cancer Res 12:3856-63. 2006
..We assessed TRAIL-R1 and TRAIL-R2 expression patterns in a large cohort of melanomas and benign nevi...
